Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Microplastics and nanoplastics (MNPs) are emerging environmental contaminants that have been detected in several human tissues, raising concerns about their potential impact on human health. However, their presence in the human pancreas has not yet been investigated.
The aim of this prospective, single-center study is to detect and characterize microplastics in human pancreatic tissue obtained from patients undergoing pancreatic resection for benign or malignant diseases. Microplastics will also be analyzed in peripancreatic adipose tissue and peripheral blood. Advanced imaging techniques, including fluorescence microscopy, confocal microscopy, and Raman spectroscopy, will be used for identification and characterization.
Secondary objectives include the evaluation of potential associations between microplastic burden and pancreatic metabolic function, assessed through clinical evaluation and metabolic testing. This proof-of-concept study aims to provide the first evidence of microplastic presence in the human pancreas and explore their potential role in metabolic dysfunction and carcinogenesis.
Microplastics and nanoplastics (MNPs) are increasingly recognized as widespread environmental contaminants with potential implications for human health. Recent evidence has demonstrated their presence in several human tissues, including lungs, placenta, cardiovascular system, and blood. However, the presence and potential role of microplastics in the human pancreas have not yet been investigated.
Preclinical studies suggest that MNP accumulation may impair pancreatic endocrine and exocrine function and contribute to carcinogenesis through mechanisms involving oxidative stress, inflammation, and cellular damage. Understanding whether microplastics accumulate in pancreatic tissue and their possible biological effects may provide new insights into pancreatic diseases, including metabolic disorders and cancer.
The PAN-Plastic study is a prospective, single-center, proof-of-concept study conducted at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The primary objective is to detect and characterize microplastics in human pancreatic tissue obtained from patients undergoing pancreatic resection for benign or malignant conditions.
Biological samples will include pancreatic tissue (both non-neoplastic and peri-neoplastic), peripancreatic adipose tissue, and peripheral blood. To minimize contamination, all samples will be collected, processed, and stored using non-plastic materials and standardized procedures.
Microplastics will be identified and characterized using a multimodal approach, including fluorescence microscopy, confocal microscopy for three-dimensional localization, and Raman spectroscopy for chemical characterization of polymer composition. This combined methodology allows for accurate detection, quantification, and classification of microplastic particles within biological tissues.
Secondary objectives include the evaluation of potential associations between microplastic burden and pancreatic metabolic function. Participants will undergo metabolic assessment, including clinical evaluation, laboratory testing, fecal elastase measurement, and oral glucose tolerance testing (OGTT) with insulin secretion modeling. Metabolic phenotypes will be classified and analyzed in relation to microplastic distribution across different biological compartments.
The study is designed as an exploratory investigation with an expected enrollment of at least 10 patients over a 12-month period. Data analysis will be primarily descriptive and aimed at identifying potential correlations and generating hypotheses for future larger-scale, multicenter studies.
This study aims to provide the first evidence of microplastic presence in human pancreatic tissue and to explore their potential role in metabolic dysfunction and pancreatic carcinogenesis.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients Undergoing Pancreatic Resection | Patients undergoing elective pancreatic resection for benign or malignant pancreatic diseases at a single tertiary referral center. Biological samples, including pancreatic tissue (non-neoplastic and peri-neoplastic), peripancreatic adipose tissue, and peripheral blood, will be collected and analyzed to detect and characterize microplastics. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Presence of Microplastics in Human Pancreatic Tissue | Detection and quantification of microplastics in human pancreatic tissue samples (non-neoplastic and peri-neoplastic), peripancreatic adipose tissue, and peripheral blood using fluorescence microscopy, confocal microscopy, and Raman spectroscopy. Microplastic burden will be expressed as number of particles per gram of tissue or per mL of blood. | At time of surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Association Between Microplastic Burden and Metabolic Function | Evaluation of the relationship between microplastic concentration in biological samples and metabolic parameters, including glucose levels, insulin secretion, C-peptide levels, and insulin sensitivity indices derived from oral glucose tolerance testing (OGTT). | Preoperative assessment |
Not provided
Inclusion Criteria:
age between 18 and 80 years patients scheduled for elective pancreatic resection for benign or malignant pancreatic disease ability to understand and provide written informed consent no contraindications to general anesthesia
Exclusion Criteria:
age <18 or >80 years severe hepatic insufficiency (Child-Pugh class C) pregnancy or breastfeeding inability to understand the study procedures or provide informed consent
Not provided
Not provided
The study population consists of adult patients undergoing elective pancreatic resection for benign or malignant pancreatic diseases at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, a tertiary referral center.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sergio Alfieri, MD | Contact | +390530155133 | sergio.alfieri@policlinicogemelli.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS di Roma | Rome | Lazio | 00168 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D010190 | Pancreatic Neoplasms |
| ID | Term |
|---|---|
| D004066 | Digestive System Diseases |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Distribution of Microplastics Across Biological Compartments | Comparison of microplastic concentration and distribution between non-neoplastic pancreatic tissue, peri-neoplastic tissue, peripancreatic adipose tissue, and peripheral blood. | At time of surgery |
| Characterization of Microplastic Particles | Chemical and morphological characterization of detected microplastics, including polymer type and particle size, using Raman spectroscopy and imaging techniques. | At time of analysis |
| D004701 |
| Endocrine Gland Neoplasms |
| D004700 | Endocrine System Diseases |